We rank companies based on fund manager, research analyst and news sentiment
BEAM stock icon

Beam Therapeutics
BEAM

$24.31
6.46%
 

About: Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Employees: 436

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 7 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

59% more call options, than puts

Call options by funds: $8.07M | Put options by funds: $5.09M

16% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 55

16% more capital invested

Capital invested by funds: $1.61B [Q3] → $1.88B (+$261M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0.19% less ownership

Funds ownership: 84.73% [Q3] → 84.54% (-0.19%) [Q4]

5% less funds holding

Funds holding: 190 [Q3] → 181 (-9) [Q4]

21% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 42

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$30
23%
upside
Avg. target
$39
59%
upside
High target
$57
134%
upside

7 analyst ratings

positive
43%
neutral
57%
negative
0%
BMO Capital
Kostas Biliouris
134%upside
$57
Outperform
Maintained
27 Mar 2024
Barclays
Gena Wang
73%upside
$42
Equal-Weight
Maintained
28 Feb 2024
RBC Capital
Luca Issi
44%upside
$35
Sector Perform
Maintained
28 Feb 2024
JP Morgan
Eric Joseph
65%upside
$40
Overweight
Upgraded
29 Jan 2024
B of A Securities
Greg Harrison
44%upside
$35
Neutral
Downgraded
15 Dec 2023

Financial journalist opinion